Freemantle N
Medicines Evaluation Group, Centre for Health Economics, University of York, Heslington, UK.
Fam Pract. 2000 Feb;17 Suppl 1:S7-10. doi: 10.1093/fampra/17.suppl_1.s7.
There is increasing information on the effectiveness of different interventions intended to reduce the gap between clinical practice and what is indicated by evidence on the effectiveness and cost-effectiveness of clinical interventions. Interventions include behavioural and financial/organizational. Unfortunately, none of the interventions have a substantial impact upon clinical practice. Many interventions that are evaluated are poorly developed, and there are several common methodological weaknesses in many of the evaluations conducted. The paper concludes with a comment on the nature of the market place for health technologies, and suggests that 'implementation interventions' may not be the solution to the problems of the poor uptake of medical research.
关于不同干预措施有效性的信息越来越多，这些干预措施旨在缩小临床实践与临床干预有效性及成本效益证据所表明的情况之间的差距。干预措施包括行为方面的和财务/组织方面的。不幸的是，没有一种干预措施对临床实践产生重大影响。许多被评估的干预措施设计不佳，并且在许多所进行的评估中有几个常见的方法学弱点。本文最后对健康技术市场的性质进行了评论，并表明“实施干预措施”可能不是解决医学研究应用不佳问题的办法。
